14 completed, 5 recruiting, 4 terminated, 3 not yet recruiting. 13 Phase 3, 9 Phase 2, 4 Phase 1, 3 Phase 4, 1 Early Phase 1.
Follow Sotagliflozin: new trials by email Literature Review of Sotagliflozin trials Research Report on Sotagliflozin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Precision T1D Platform - New Therapies for Cardio-Renal Complications Finerenone, Sotagliflozin - Type 1 Diabetes, T1D Heart Failure | Phase 2 | Not yet recruiting | Oregon Health and Science University | 57 | 2026-11-01 | 2026-08-10 |
| Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity Sotagliflozin, Placebo - Anthracycline-induced Cardiotoxicity, Lymphoma | Phase 2 | Not yet recruiting | Icahn School of Medicine at Mount Sinai | 60 | 2026-07-01 | 2026-05-07 |
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| Antithrombotic Activities of Sotagliflozin vs. Empagliflozin Sotagliflozin, Empagliflozin - Thrombosis | Phase 4 | Completed | Icahn School of Medicine at Mount Sinai | 17 | 2025-02-25 | 2026-04-30 |
| Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia Sotagliflozin, Placebo - Nephropathy, Diabetic Nephropathies | Phase 2 | Not yet recruiting | Steno Diabetes Center Copenhagen | 69 | 2025-02-01 | 2025-01-27 |
| Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes Sotagliflozin, Placebo - Type 1 Diabetes, Heart Failure | Phase 2 | Recruiting | University of Dundee | 320 | 2025-01-28 | 2026-04-06 |
| Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy Sotagliflozin - Hypertrophic Cardiomyopathy Without Obstruction | Early Phase 1 | Recruiting | University of Pennsylvania | 26 | 2024-12-17 | 2026-02-11 |
| Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression Sotagliflozin - Cardiac Sarcoidosis | Recruiting | University of Pennsylvania | 40 | 2024-11-20 | 2026-01-07 | |
| Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease Sotagliflozin, Placebo - Diabetic Nephropathies, Kidney Failure, Chronic | Phase 3 | Recruiting | Alessandro Doria | 150 | 2024-10-31 | 2026-03-24 |
| A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy Sotagliflozin, Placebo - Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy | Phase 3 | Active not recruiting | Lexicon Pharmaceuticals | 500 | 2024-09-24 | 2026-08-26 |
| Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes Sotagliflozin, Volagidemab - Type 1 Diabetes | Phase 1 / Phase 2 | Active not recruiting | University of California, San Diego | 24 | 2024-09-09 | 2026-06-15 |
| Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes Aspirin tablet, Semaglutide, Sotagliflozin - Cardiovascular Diseases, Heart Failure | Phase 3 | Recruiting | Steno Diabetes Center Copenhagen | 2000 | 2024-07-01 | 2025-01-10 |
| Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients Sotagliflozin, Placebo - Heart Failure With Preserved Ejection Fraction | Phase 4 | Completed | Juan Badimon | 88 | 2022-10-26 | 2026-06-24 |
| Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial) Sotagliflozin, Placebo - Heart Failure, Type 2 Diabetes Mellitus | Phase 3 | Terminated | Lexicon Pharmaceuticals | 1222 | 2018-06-15 | 2022-10-28 |
| Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control Sotagliflozin, Placebo - Type 2 Diabetes Mellitus | Phase 3 | Terminated | Lexicon Pharmaceuticals | 376 | 2018-02-19 | 2021-06-25 |
| Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk Sotagliflozin, Placebo - Heart Failure, Type 2 Diabetes Mellitus | Phase 3 | Terminated | Lexicon Pharmaceuticals | 10584 | 2017-12-19 | 2022-10-28 |
| Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure Sotagliflozin, Placebo - Cardiac Failure Aggravated | Phase 2 | Terminated | Lexicon Pharmaceuticals | 32 | 2017-12-04 | 2021-05-11 |
| Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin Sotagliflozin, Empagliflozin, Placebo - Type 2 Diabetes Mellitus | Phase 3 | Completed | Lexicon Pharmaceuticals | 770 | 2017-11-27 | 2021-05-11 |
| Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents Sotagliflozin, Insulin glargine (HOE901), Placebo - Type 2 Diabetes Mellitus | Phase 3 | Completed | Lexicon Pharmaceuticals | 571 | 2017-09-15 | 2021-05-11 |
| A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control Placebo, Sotagliflozin - Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 4 | Phase 3 | Completed | Lexicon Pharmaceuticals | 277 | 2017-08-16 | 2021-06-25 |
Showing 20 of 30. Sign in to see all of them.
Diabetes Mellitus, Type 1 (12) · Diabetes Mellitus, Type 2 (8) · Heart Failure (7) · Renal Insufficiency, Chronic (4) · Albuminuria (2) · Cardiovascular Diseases (2) · Diabetic Nephropathies (2) · Renal Insufficiency (2) · Cardiomyopathy, Hypertrophic (1) · Cardiotoxicity (1) · Hyperkalemia (1) · Hypoxia (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1) · Lymphoma (1)
Lexicon Pharmaceuticals (18) · Icahn School of Medicine at Mount Sinai (2) · Steno Diabetes Center Copenhagen (2) · University of Pennsylvania (2) · Alessandro Doria (1) · Baylor Research Institute (1) · Juan Badimon (1) · Oregon Health and Science University (1) · University of California, San Diego (1) · University of Dundee (1)
United States (26) · Canada (10) · United Kingdom (9) · Hungary (8) · Italy (8) · France (7) · Germany (7) · Israel (7) · Poland (7) · Spain (7) · Argentina (6) · Bulgaria (6) · Czechia (6) · Romania (6) · Russia (6)
Suman Wason, MD (11) · Sangeeta Sawhney, M.D. (3) · Carlos G Santos-Gallego, MD (2) · Juan J Badimon (2) · Alessandro Doria, MD PhD MPH (1) · David Cherney, MD PhD (1) · Ify Mordi, MBChB, MD (1) · Michael Mauer, MD (1) · Paco Bravo, MD (1) · Paul Strumph, M.D. (1) · Peter Rossing, MD, DMSc, Proffessor (1) · Rodica Busui, MD, PhD (1) · Sangeeta Sawhney, MD (1) · Sharlene Day, MD (1)
PMID 38770818, PMID 30833371, PMID 31587812, PMID 32721228, PMID 32928957, PMID 13148192, PMID 14899212, PMID 16315784, PMID 20013165, PMID 21629130, PMID 21732228, PMID 23002195, PMID 26049551, PMID 28899222, PMID 29937430, PMID 29937431, PMID 30819210, PMID 30999996, PMID 31264767, PMID 32479196, PMID 32640846, PMID 33200891, PMID 33200892, PMID 33334875, PMID 34152828, PMID 34338408, PMID 34675108, PMID 35603596, PMID 36266774, PMID 36474124, PMID 36782093, PMID 36823484, PMID 37318685, PMID 38277468, PMID 38771012, PMID 38878007, PMID 39078403, PMID 39260929, PMID 39918875, PMID 39961315, PMID 40748666, PMID 42815751, PMID 709777, PMID 8417889
2016 (4), 2017 (4), 2014 (1), R61HL164376 (1)